| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cifra de Afaceri - Ron | 414.877 | 430.485 | 479.326 | 530.966 | 571.375 | 724.578 | 656.502 | 744.499 | 787.517 | 815.961 |
| Venituri Totale - Ron | 414.906 | 430.505 | 479.354 | 530.987 | 571.403 | 724.623 | 656.557 | 744.564 | 787.849 | 816.034 |
| Cheltuieli Totale - Ron | 387.425 | 415.071 | 455.389 | 486.633 | 517.026 | 632.216 | 582.429 | 659.116 | 711.092 | 762.227 |
| Profit/Pierdere Brut - Ron | 27.481 | 15.434 | 23.965 | 44.354 | 54.377 | 92.407 | 74.128 | 85.448 | 76.757 | 53.807 |
| Profit/Pierdere Net - Ron | 23.084 | 11.129 | 19.171 | 39.044 | 48.663 | 85.520 | 67.562 | 78.002 | 69.077 | 45.370 |
| Salariati | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Verifica rapoartele financiare pentru firma - Silvapharm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Active Imobilizate | 44.681 | 30.429 | 16.505 | 3.359 | 0 | 0 | 0 | 0 | 0 | 0 |
| Active Circulante | 269.631 | 162.898 | 159.204 | 214.576 | 219.347 | 254.493 | 290.194 | 247.181 | 276.991 | 248.118 |
| Stocuri | 82.671 | 84.086 | 80.435 | 72.459 | 72.530 | 86.732 | 80.835 | 89.009 | 97.060 | 107.935 |
| Creante | 37.949 | 10.851 | 49.332 | 68.629 | 59.925 | 86.920 | 73.606 | 85.244 | 75.720 | 53.010 |
| Casa si conturi | 149.011 | 67.961 | 29.437 | 73.488 | 86.892 | 80.841 | 135.753 | 72.928 | 104.211 | 87.173 |
| Capitaluri Proprii | 190.062 | 11.329 | 19.371 | 39.244 | 48.863 | 85.720 | 101.282 | 119.284 | 118.361 | 87.731 |
| Capital Social | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 |
| Datorii | 124.250 | 181.998 | 156.338 | 178.691 | 170.484 | 168.773 | 188.912 | 127.897 | 158.630 | 160.387 |
| Venituri in Avans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Curs valutar - RON | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CAEN Principal | "4773 - 4773" | |||||||||
| CAEN An Financiar |
4773
|
|||||||||
Comentarii - Silvapharm S.r.l.